Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AMBRX BIOPHARMA INC.

(AMAM)
  Report
Delayed Nyse  -  03:35 2022-09-23 pm EDT
1.058 USD   -3.78%
09/21Baird Adjusts Ambrx Biopharma Price Target to $8 From $16, Maintains Outperform
MT
08/30SECTOR UPDATE : Health Care Stocks Rebound Slightly in Late Trade, Pare Losses
MT
08/30SECTOR UPDATE : Health Care Stocks Dropping Tuesday Afternoon
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ambrx Biopharma Names Kate Hermans Interim CEO

08/16/2022 | 04:22pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AMBRX BIOPHARMA INC. -3.78% 1.0584 Delayed Quote.-88.28%
BRISTOL-MYERS SQUIBB COMPANY -0.81% 70.71 Delayed Quote.13.41%
PFIZER, INC. -1.10% 44.08 Delayed Quote.-25.35%
All news about AMBRX BIOPHARMA INC.
09/21Baird Adjusts Ambrx Biopharma Price Target to $8 From $16, Maintains Outperform
MT
08/30SECTOR UPDATE : Health Care Stocks Rebound Slightly in Late Trade, Pare Losses
MT
08/30SECTOR UPDATE : Health Care Stocks Dropping Tuesday Afternoon
MT
08/29Ambrx Biopharma Narrows Net Loss for First Half of 2022, Revenue Declines
MT
08/29Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update
BU
08/29Ambrx Biopharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/16Ambrx Biopharma Names Kate Hermans Interim CEO
MT
08/16Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian
BU
08/16Ambrx Biopharma Inc. Announces Executive Changes
CI
08/16Ambrx Biopharma Inc. Announces CEO Changes
CI
More news
Analyst Recommendations on AMBRX BIOPHARMA INC.
More recommendations
Financials (USD)
Sales 2022 5,71 M - -
Net income 2022 -87,4 M - -
Net cash 2022 14,4 M - -
P/E ratio 2022 -3,26x
Yield 2022 -
Capitalization 40,9 M 40,9 M -
EV / Sales 2022 4,63x
EV / Sales 2023 -22,1x
Nbr of Employees 81
Free-Float 100%
Chart AMBRX BIOPHARMA INC.
Duration : Period :
Ambrx Biopharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,06 $
Average target price 6,67 $
Spread / Average Target 530%
EPS Revisions
Managers and Directors
Kate Hermans President, Chief Executive Officer & Director
Sonja Nelson Chief Financial Officer
Katrin Rupalla Chairman
Janice Lu Chief Medical Officer
Xiaowei Chang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AMBRX BIOPHARMA INC.-88.28%41
MODERNA, INC.-51.32%48 368
IQVIA HOLDINGS INC.-32.86%35 330
LONZA GROUP AG-41.68%33 599
SEAGEN INC.-9.96%25 673
ALNYLAM PHARMACEUTICALS, INC.18.40%24 099